CN107635993B - 取代的三环杂环化合物 - Google Patents

取代的三环杂环化合物 Download PDF

Info

Publication number
CN107635993B
CN107635993B CN201680026733.XA CN201680026733A CN107635993B CN 107635993 B CN107635993 B CN 107635993B CN 201680026733 A CN201680026733 A CN 201680026733A CN 107635993 B CN107635993 B CN 107635993B
Authority
CN
China
Prior art keywords
phenyl
pyrrolo
imidazo
dihydro
pyridin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201680026733.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN107635993A (zh
Inventor
H-Y·肖
T·G·M·达尔
段敬武
江斌
A·J·帝本
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of CN107635993A publication Critical patent/CN107635993A/zh
Application granted granted Critical
Publication of CN107635993B publication Critical patent/CN107635993B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/06—Peri-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Epidemiology (AREA)
CN201680026733.XA 2015-03-18 2016-03-17 取代的三环杂环化合物 Active CN107635993B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562134769P 2015-03-18 2015-03-18
US62/134,769 2015-03-18
PCT/US2016/022737 WO2016149436A1 (en) 2015-03-18 2016-03-17 Substituted tricyclic heterocyclic compounds

Publications (2)

Publication Number Publication Date
CN107635993A CN107635993A (zh) 2018-01-26
CN107635993B true CN107635993B (zh) 2020-05-22

Family

ID=55640932

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680026733.XA Active CN107635993B (zh) 2015-03-18 2016-03-17 取代的三环杂环化合物

Country Status (14)

Country Link
US (1) US10189840B2 (OSRAM)
EP (1) EP3271360B1 (OSRAM)
JP (1) JP6793657B2 (OSRAM)
KR (1) KR102654709B1 (OSRAM)
CN (1) CN107635993B (OSRAM)
AU (1) AU2016233288A1 (OSRAM)
BR (1) BR112017019773A2 (OSRAM)
CA (1) CA2980159A1 (OSRAM)
EA (1) EA032315B1 (OSRAM)
ES (1) ES2797805T3 (OSRAM)
IL (1) IL254424A0 (OSRAM)
MX (1) MX2017011434A (OSRAM)
SG (1) SG11201707469WA (OSRAM)
WO (1) WO2016149436A1 (OSRAM)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016149439A1 (en) 2015-03-18 2016-09-22 Bristol-Myers Squibb Company Heterocyclic compounds useful as inhibitors of tnf
CA2982446A1 (en) 2015-03-18 2016-09-22 Bristol-Myers Squibb Company Tricyclic heterocyclic compounds useful as inhibitors of tnf
EP3294726A1 (en) 2015-04-17 2018-03-21 AbbVie Inc. Indazolones as modulators of tnf signaling
WO2016168641A1 (en) 2015-04-17 2016-10-20 Abbvie Inc. Tricyclic modulators of tnf signaling
AR104293A1 (es) 2015-04-17 2017-07-12 Abbvie Inc Indazolonas como moduladores de la señalización de tnf
GB201510758D0 (en) 2015-06-18 2015-08-05 Ucb Biopharma Sprl Novel TNFa structure for use in therapy
EP3331889B1 (en) 2015-08-03 2020-09-23 Bristol-Myers Squibb Company Cyclic compounds useful as modulators of tnf alpha
GB201621907D0 (en) 2016-12-21 2017-02-01 Ucb Biopharma Sprl And Sanofi Antibody epitope
WO2018167176A1 (en) 2017-03-15 2018-09-20 Ucb Biopharma Sprl Fused pentacyclic imidazole derivatives as modulators of tnf activity

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101687865A (zh) * 2007-06-26 2010-03-31 塞诺菲-安万特股份有限公司 稠合的苯并咪唑和氮杂苯并咪唑的区域选择性金属催化合成
CN101772499A (zh) * 2007-08-02 2010-07-07 赛诺菲-安万特 三环n-杂芳基-甲酰胺衍生物、其制备和其治疗用途
CN102325753A (zh) * 2008-12-19 2012-01-18 百时美施贵宝公司 用作激酶抑制剂的咔唑甲酰胺化合物
CN104428293A (zh) * 2012-06-11 2015-03-18 Ucb生物制药私人有限公司 调节TNFα的苯并咪唑类

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6038397B2 (ja) * 1980-03-06 1985-08-31 エスエス製薬株式会社 チアジノイミダゾ−ル誘導体及びその製造法
AU741772B2 (en) 1997-02-25 2001-12-06 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Substituted benzimidazoles as non-nucleoside inhibitors of reverse transcriptase
EP1224185B1 (en) * 1999-10-27 2005-11-30 Novartis AG Thiazole and imidazo[4,5-b]pyridine compounds and their pharmaceutical use
US7601846B2 (en) 2001-06-26 2009-10-13 The Regents Of The University Of California Compounds having activity as inhibitors of apoptosis
EP1479681A4 (en) 2002-01-31 2006-05-10 Daiichi Seiyaku Co IMIDAZO (1,2-a) pyridine
WO2004050035A2 (en) 2002-12-03 2004-06-17 Isis Pharmaceuticals, Inc. Benzimidazoles and analogs thereof as antivirals
US20050124638A1 (en) 2003-12-08 2005-06-09 Swayze Eric E. Benzimidazoles and analogs thereof as antivirals
EP2209785A1 (en) 2007-10-05 2010-07-28 S*BIO Pte Ltd 2-morpholinylpurines as inhibitors of pi3k
JP2009227599A (ja) 2008-03-21 2009-10-08 Daiichi Sankyo Co Ltd イミダゾピリダジン誘導体
CN101717397B (zh) 2008-10-09 2012-11-28 中国科学院上海药物研究所 一类取代吡啶并[2',1':2,3]咪唑并[4,5-c]异喹啉酮类化合物及其合成方法和用途,以及包含该类化合物的药物组合物
US8691187B2 (en) 2009-03-23 2014-04-08 Eli Lilly And Company Imaging agents for detecting neurological disorders
JP2012521988A (ja) 2009-03-23 2012-09-20 シーメンス メディカル ソリューションズ ユーエスエー インコーポレイテッド 神経学的障害を検知するためのイメージング剤
WO2012148550A1 (en) 2011-02-25 2012-11-01 Myrexis, Inc. Prodrugs of therapeutic compounds
EP2527344A1 (en) 2011-05-25 2012-11-28 Almirall, S.A. Pyridin-2(1H)-one derivatives useful as medicaments for the treatment of myeloproliferative disorders, transplant rejection, immune-mediated and inflammatory diseases
WO2014009295A1 (en) 2012-07-13 2014-01-16 Ucb Pharma S.A. Imidazopyridine derivatives as modulators of tnf activity
GB201212513D0 (en) 2012-07-13 2012-08-29 Ucb Pharma Sa Therapeutic agents
GB201321746D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
JP6469692B2 (ja) 2013-12-09 2019-02-13 ユーシービー バイオファルマ エスピーアールエル Ｔｎｆ活性のモジュレーターとしてのイミダゾピリジン誘導体
GB201321738D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic Agents
GB201321741D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
RU2685234C1 (ru) 2013-12-09 2019-04-17 Юсб Байофарма Спрл Конденсированные бициклические гетероароматические производные в качестве модуляторов активности tnf
GB201321735D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic Agents
GB201321737D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic Agents
GB201321745D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321742D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321744D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321743D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321739D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
AU2015328414B2 (en) 2014-10-06 2020-03-19 Signal Pharmaceuticals, Llc Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith
WO2016149439A1 (en) 2015-03-18 2016-09-22 Bristol-Myers Squibb Company Heterocyclic compounds useful as inhibitors of tnf
CA2982446A1 (en) 2015-03-18 2016-09-22 Bristol-Myers Squibb Company Tricyclic heterocyclic compounds useful as inhibitors of tnf

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101687865A (zh) * 2007-06-26 2010-03-31 塞诺菲-安万特股份有限公司 稠合的苯并咪唑和氮杂苯并咪唑的区域选择性金属催化合成
CN101772499A (zh) * 2007-08-02 2010-07-07 赛诺菲-安万特 三环n-杂芳基-甲酰胺衍生物、其制备和其治疗用途
CN102325753A (zh) * 2008-12-19 2012-01-18 百时美施贵宝公司 用作激酶抑制剂的咔唑甲酰胺化合物
CN104428293A (zh) * 2012-06-11 2015-03-18 Ucb生物制药私人有限公司 调节TNFα的苯并咪唑类

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Synthesis and Antitumour Activity of 1H,3H-Thiazolo[3,4-a]benzimidazole Derivatives;ALBA CHIMIRRI ET AL;《ARCHIV DER PHARMAJIE》;20011231;第334卷(第6期);203-208 *

Also Published As

Publication number Publication date
EP3271360A1 (en) 2018-01-24
IL254424A0 (en) 2017-11-30
US10189840B2 (en) 2019-01-29
JP2018508553A (ja) 2018-03-29
EA032315B1 (ru) 2019-05-31
JP6793657B2 (ja) 2020-12-02
CA2980159A1 (en) 2016-09-22
EA201792034A1 (ru) 2018-03-30
SG11201707469WA (en) 2017-10-30
ES2797805T3 (es) 2020-12-03
KR102654709B1 (ko) 2024-04-03
AU2016233288A1 (en) 2017-11-09
KR20170129810A (ko) 2017-11-27
US20180111936A1 (en) 2018-04-26
EP3271360B1 (en) 2020-04-22
BR112017019773A2 (pt) 2018-05-15
CN107635993A (zh) 2018-01-26
WO2016149436A1 (en) 2016-09-22
MX2017011434A (es) 2018-01-25

Similar Documents

Publication Publication Date Title
CN107635993B (zh) 取代的三环杂环化合物
CN113272303B (zh) 嘧啶并五元氮杂环类衍生物、其制备方法及其在医药上的应用
CN108137609B (zh) 用作TNFα的调节剂的环状化合物
CN107635992B (zh) 用作tnf抑制剂的三环杂环化合物
JP6779899B2 (ja) Ｔｎｆ阻害剤として有用なヘテロ環式化合物
CN108137547A (zh) 可用作TNFα调节剂的杂环化合物
CN107108555B (zh) 三环阻转异构体化合物
TWI833819B (zh) 用於治療與apj受體活性相關的病狀的化合物及組成物
TW202421626A (zh) 衍生物
CN107148409A (zh) 经取代的二环化合物
CN105524053A (zh) 四氢苯并噻吩化合物
CN112574212B (zh) 一种嘧啶并五元氮杂环类衍生物、其制备方法及其在医药上的应用
CN110167930A (zh) RORγ调节剂
HK40059423A (en) Pyrimidine and five-membered nitrogen heterocycle derivative, preparation method therefor, and medical uses thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant